United Kingdom· GB-APID-42643611000001104
Omjjara 100mg tablets
A momelotinib product containing momelotinib, registered in United Kingdom by GlaxoSmithKline UK Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Momelotinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Momelotinib · ATC L01EJ04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of momelotinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Momelotinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$309.44
- FR France$0.16
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Momelotinib
- Manufacturer
- GlaxoSmithKline UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01EJ04
- ATC class
- Momelotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 5
- gtin05054290006612
- gtin5054290006582
- gtin05054290006582
- gtin5054290006612
- gtin05054290010626
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Momelotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesOjjaaraGlaxoSmithKline LLC
- CanadaOJJAARAGLAXOSMITHKLINE INC
- SwitzerlandOmjjara 100 mg, FilmtablettenGlaxoSmithKline AG
- CzechiaOMJJARAGlaxoSmithKline Trading Services Limited, Dublin
- SpainOMJJARA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGlaxosmithkline Trading Services Limited
- FinlandOmjjaraGlaxosmithkline Trading Services Limited
- FranceOMJJARA 100 mg, comprimé pelliculéGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- IrelandOmjjara 100 mg film-coated tabletsGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omjjara
- Liechtenstein · Omjjara
- Norway · Omjjara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/91fbc9cc-9722-4b1d-9c81-0beb4f5b4da2 GET /v1/drugs/91fbc9cc-9722-4b1d-9c81-0beb4f5b4da2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42643611000001104",
"desc": "Omjjara 100mg tablets (GlaxoSmithKline UK Ltd)",
"form": "Oral tablet",
"vpid": "42655811000001104",
"source": "dmd",
"vtm_id": "42649711000001106",
"strength": "100 mg",
"substance": "Momelotinib",
"ingredient": "Momelotinib dihydrochloride monohydrate",
"supplier_code": "4012301000001105"
}See everything about momelotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.